Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection

Stock Track

Aug 11

Amphastar Pharmaceuticals (AMPH) stock surged 8.81% in pre-market trading on Monday following the announcement of a significant regulatory milestone. The company has secured U.S. Food and Drug Administration (FDA) approval for its generic Iron Sucrose Injection, a development that has excited investors and boosted confidence in the company's growth prospects.

The FDA has granted approval for Amphastar's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP, in single-dose vials of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. This injectable medication is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease, addressing a significant medical need. The company plans to launch the product in the third quarter of 2025, potentially opening up a substantial new revenue stream.

Market analysts are particularly optimistic about this approval, as it positions Amphastar to compete in a lucrative market. The comparable product, Venofer®, generated approximately $513 million in sales over the past year. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, emphasizing the company's commitment to developing complex generics and maintaining high regulatory standards. This FDA nod not only validates Amphastar's R&D capabilities but also strengthens its product portfolio in the specialty pharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1133820007"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133820007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133820007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133820007","market":"nz","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection","media":"Stock Track","content":"<p>Amphastar Pharmaceuticals (AMPH) stock surged 8.81% in pre-market trading on Monday following the announcement of a significant regulatory milestone. The company has secured U.S. Food and Drug Administration (FDA) approval for its generic Iron Sucrose Injection, a development that has excited investors and boosted confidence in the company's growth prospects.</p>\n\n<p>The FDA has granted approval for Amphastar's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP, in single-dose vials of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. This injectable medication is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease, addressing a significant medical need. The company plans to launch the product in the third quarter of 2025, potentially opening up a substantial new revenue stream.</p>\n\n<p>Market analysts are particularly optimistic about this approval, as it positions Amphastar to compete in a lucrative market. The comparable product, Venofer®, generated approximately $513 million in sales over the past year. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, emphasizing the company's commitment to developing complex generics and maintaining high regulatory standards. This FDA nod not only validates Amphastar's R&D capabilities but also strengthens its product portfolio in the specialty pharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-11 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amphastar Pharmaceuticals (AMPH) stock surged 8.81% in pre-market trading on Monday following the announcement of a significant regulatory milestone. The company has secured U.S. Food and Drug Administration (FDA) approval for its generic Iron Sucrose Injection, a development that has excited investors and boosted confidence in the company's growth prospects.</p>\n\n<p>The FDA has granted approval for Amphastar's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP, in single-dose vials of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. This injectable medication is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease, addressing a significant medical need. The company plans to launch the product in the third quarter of 2025, potentially opening up a substantial new revenue stream.</p>\n\n<p>Market analysts are particularly optimistic about this approval, as it positions Amphastar to compete in a lucrative market. The comparable product, Venofer®, generated approximately $513 million in sales over the past year. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, emphasizing the company's commitment to developing complex generics and maintaining high regulatory standards. This FDA nod not only validates Amphastar's R&D capabilities but also strengthens its product portfolio in the specialty pharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1133820007","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133820007","pubTimestamp":1754915066,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amphastar Pharmaceuticals (AMPH) stock surged 8.81% in pre-market trading on Monday following the announcement of a significant regulatory milestone. The company has secured U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"股票追踪|FDA批准仿制药蔗糖铁注射液Amphastar Pharmaceuticals盘前飙升8.81%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Amphastar Pharmaceuticals (AMPH) stock surged 8.81% in pre-market trading on Monday following the announcement of a significant regulatory milestone. The company has secured U.S. Food and Drug Administration (FDA) approval for its generic Iron Sucrose Injection, a development that has excited investors and boosted confidence in the company's growth prospects.\nThe FDA has granted approval for Amphastar's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP, in single-dose vials of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. This injectable medication is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease, addressing a significant medical need. The company plans to launch the product in the third quarter of 2025, potentially opening up a substantial new revenue stream.\nMarket analysts are particularly optimistic about this approval, as it positions Amphastar to compete in a lucrative market. The comparable product, Venofer®, generated approximately $513 million in sales over the past year. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, emphasizing the company's commitment to developing complex generics and maintaining high regulatory standards. This FDA nod not only validates Amphastar's R&D capabilities but also strengthens its product portfolio in the specialty pharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}